Buy side advisory to Affidea on the acquisition of NU-MED Group from Enterprise Investors

Acquisition of NU-MED Group by Affidea 

Date: July 2024
Country: Poland
Industry: Healthcare
Target: NU-MED Group
Buyer (Client): Affidea
Seller: Enterprise Investors
VCP’s role: Buy side M&A advisor

• VCP acted as an exclusive investment banking advisor to Affidea Group, a pan-European provider of advanced diagnostics and outpatient services and a portfolio company of Groupe Bruxelles Lambert (GBL), on the acquisition of NU-MED Group, the operator of four specialized medical facilities diagnosing and treating cancer patients from Enterprise Investors
• With over 17 years of experience, NU-MED Group is a leading healthcare provider offering comprehensive oncological treatment, including radiotherapy, brachytherapy and chemotherapy through its oncological outpatient clinics
• The acquisition enhances Affidea’s capabilities in Poland by adding comprehensive radiotherapy services and further strengthening the integrated cancer care services that Affidea provides across its European footprint
• VCP provided the buyer with full scope investment banking services including coordination of all advisory workstreams (Finance, Tax, Legal, Operations and IT), valuation support, provision of deal tactics and strategy as well as support in negotiations of transaction documentation and other ad hoc assignments
• The transaction was signed in an expeditious manner in July 2024, taking less than two months to process highly demanding project
• The financial terms of the deal are not disclosed. The transaction is subject to approval by the Polish antitrust regulator UOKiK and is expected to be closed in Q4 2024